Investigational drug · Phase 3
Tociluzumab
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Relapsed or Refractory Follicular Lymphoma.
Phase 3Last checked: Nov 19, 2026Latest source record: Oct 8, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
5
Any phase or sponsor naming "Tociluzumab"
First trial start
2021
Oct 27, 2021
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Tociluzumab", any sponsor or status.
Conditions studied
As listed on its trial records.
- Relapsed or Refractory Follicular Lymphoma
Approved drugs for the same conditions: Lymphoma (non-Hodgkin) · Hematology and blood cancers
Largest trials
Live from ClinicalTrials.gov: studies naming "Tociluzumab" as an intervention, largest first.
- A Study Evaluating the Efficacy and Safety of Mosunetuzumab in Combination With Lenalidomide in Comparison to Rituximab in Combination With Lenalidomide With a US Extension of Mosunetuzumab in Combination With Lenalidomide in Participants With Follicular LymphomaPivotal-lookingActive, not recruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT04712097 · 478 participants · Start Oct 27, 2021 · Primary completion Jun 3, 2026
Drug: Mosunetuzumab; Lenalidomide and 2 more · For: Relapsed or Refractory Follicular Lymphoma
Sites: Duarte, California; Atlanta, Georgia; Fort Wayne, Indiana · 111 sites in all
- Efficacy and Safety of Remdesivir and Tociluzumab for the Management of Severe COVID-19: A Randomized Controlled TrialPivotal-lookingCompleted
M Abdur Rahim Medical College and HospitalGovernment (non-federal)
NCT04678739 · 205 participants · Start Aug 15, 2020 · Primary completion Jan 30, 2021
Drug: Remdesivir; Tocilizumab · For: Covid19; Covid-19 ARDS
Sites: Chittagong, Bangladesh; Cox’s Bāzār, Bangladesh; Dinajpur, Bangladesh · 4 sites in all
Christian HassagerAcademic, hospital or other
NCT03863015 · 80 participants · Start Mar 4, 2019 · Primary completion Dec 23, 2019
Drug: Tocilizumab 20 Mg/mL Intravenous Solution; isotonic saline · For: Heart Arrest; Out-Of-Hospital Cardiac Arrest; Systemic Inflammatory Response Syndrome
Sites: Copenhagen, Denmark
National Institute of Allergy and Infectious Diseases (NIAID)NIH
NCT05463133 · 50 participants (planned) · Start Jul 8, 2022 · Primary completion Dec 31, 2032
Drug: Sirolimus; Cyclophosphamide and 6 more · For: Chronic Granulomatous Disease
Sites: Bethesda, Maryland
- Tocilizumab for the Treatment of Cytokine Release Syndrome in Patients With COVID-19 (SARS-CoV-2 Infection)Pivotal-lookingWithdrawn
Emory UniversityAcademic, hospital or other
NCT04361552 · 0 participants · Start Apr 7, 2020 · Primary completion Jun 2, 2020
Drug: Tocilizumab · For: Cerebrovascular Accident; Chronic Obstructive Pulmonary Disease; Chronic Renal Failure and 4 more
Sites: Atlanta, Georgia
Newest research
PubMed records naming it or its code names, newest first.
- Hemophagocytic lymphohistiocytosis associated with immune checkpoint inhibitor use: A review of the current knowledge and future directions.
Walmsley CS, Schoepflin Z, De Brabandt C, et al. · Blood Cells Mol Dis 2025
- Maternal and Fetal Outcome in Pregnant Women With Critical COVID-19 Treated With Tocilizumab in a Tertiary Care Hospital in Dubai.
Isaac B, Hazari K, Harb DK, et al. · Cureus 2023
- Use of Tociluzumab in the Thrombocytopenic COVID-19 Patient: A Challenge in the Therapeutic Approach.
Kuscu OO, Ergenoglu P · Rom J Anaesth Intensive Care 2021
- Insight in the Current Progress in the Largest Clinical Trials for Covid-19 Drug Management (As of January 2021).
Panovska-Stavridis I, Ridova N, Stojanoska T, et al. · Pril (Makedon Akad Nauk Umet Odd Med Nauki) 2021
- Drug-induced subacute cutaneous lupus erythematosus associated with abatacept.
Figueredo Zamora E, Callen JP, Schadt CR · Lupus 2021
- Post-transplant patients with COVID-19 associated acute respiratory distress syndrome, a role for Tociluzumab: A case series.
Ladna M, Villanueva FL, Maharrey PB, et al. · Respir Med Case Rep 2021
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Roche (Genentech).
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.